clinical trial · NCT07535034
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
GoutDotinuradPlacebo
brief summary
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
started
Apr 1, 2026
primary completion
Jul 1, 2027
completion
Aug 1, 2027
last updated
Apr 16, 2026
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad in Adult Participants With Gout Who Are Intolerant to Xanthine Oxidase Inhibitors or Failed Uricase Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol